CRISPR-Enabled Nanocarrier Systems Against Multidrug-Resistant Bacteria: Emerging Potential of Bilosomes for Precision Antimicrobial Therapy

Authors

Abstract

Objective(s): This review aims to evaluate the mechanistic convergence of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas genome-targeting technology with bile salt-stabilized vesicular nanocarriers (bilosomes) to circumvent physiological barriers and achieve sequence-specific eradication of multidrug-resistant (MDR) bacterial pathogens. Data sources: A systematic literature search was conducted across PubMed/MEDLINE, Web of Science, Scopus, ScienceDirect, and Google Scholar covering peer-reviewed studies published up to 2026. Study selection: Articles encompassing molecular mechanisms of antimicrobial resistance, CRISPR-Cas antimicrobials, non-viral nucleic acid delivery systems, and bilosomal formulations were critically scrutinized. Summary of contents of the article: Multidrug-resistant bacteria make regular antibiotics less effective and complicate clinical therapy. CRISPR-Cas technology can identify specific genomic loci and target resistance genes, virulence determinants, and plasmid scaffolds. However, therapeutic utilization is severely impeded by nuclease vulnerability, poor bacterial penetration, and transient stability. Bilosomes—lipid vesicles incorporated with deoxycholate, glycocholate, or taurocholate—exhibit superior membrane flexibility, resistance to gastrointestinal and enzymatic degradation, and enhanced cellular permeation compared to conventional liposomes. Functionalizing bilosomes with targeting ligands enables localized delivery and sustained release of Cas9 ribonucleoprotein complexes, driving sequence-specific chromosomal double-strand breaks, plasmid curing, and resensitization to conventional antibiotics. Conclusion: CRISPR-loaded bilosomal nanocarriers offer an effective non-antibiotic delivery platform capable of degrading bacterial chromosomes, curing high-risk resistance plasmids (blaKPC, blaNDM, mcr-1), and selectively reducing pathogen load without triggering broad microbiome dysbiosis.

Keywords: Multidrug-resistant bacteria (MDR), CRISPR-Cas, Bilosomes, Nanocarrier delivery, Antimicrobial resistance (AMR), Plasmid curing, Precision antimicrobial therapy.

Keywords:

Multidrug-resistant bacteria (MDR), CRISPR-Cas, Bilosomes, Nanocarrier delivery, Antimicrobial resistance (AMR), Plasmid curing, Precision antimicrobial therapy

DOI

https://doi.org/10.22270/jddt.v16i11.8085

Author Biographies

Dipu Pan, Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Shubhajit Sarkar, Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Bipasha De, Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Amit Mia, Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Ratnaprava Das, Derozio Pharma Institute, West Bengal University of Health Science, West Bengal, India.

Derozio Pharma Institute, West Bengal University of Health Science, West Bengal, India.

Soumita Guha, Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Sachin Biswas, Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Division in Pharmaceutics, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Risha Saha, Division in Pharmacognosy, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Division in Pharmacognosy, Department of Pharmaceutical Technology, University of North Bengal, West Bengal, India.

Sudipta Mukherjee, Division in Pharmacology, Gupta College of Technological Sciences, West Bengal, India.

Division in Pharmacology, Gupta College of Technological Sciences, West Bengal, India.

Sagarika Ghosh, Division in Pharmacology, Department of Pharmaceutical Technology, Maulana Abul Kalam Azad University of Technology, West Bengal, India.

Division in Pharmacology, Department of Pharmaceutical Technology, Maulana Abul Kalam Azad University of Technology, West Bengal, India.

References

1. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al., Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, Lancet, 2022; 399(10325):629-655.

2. Mancuso G, Midiri A, Gerace E, Biondo C, Bacterial antibiotic resistance: the most critical pathogens, Pathogens, 2021; 10(10):1310. https://doi.org/10.3390/pathogens10101310 PMid:34684258 PMCid:PMC8541462

3. Ventola CL, The antibiotic resistance crisis: part 1: causes and threats, Pharmacy and Therapeutics, 2015; 40(4):277-283.

4. Levy SB, Marshall B, Antibacterial resistance worldwide: causes, challenges and responses, Nature Medicine, 2004; 10(Suppl 12):S122-S129. https://doi.org/10.1038/nm1145 PMid:15577930

5. Partridge SR, Kwong SM, Firth N, Jensen SO, Mobile genetic elements associated with antimicrobial resistance, Clinical Microbiology Reviews, 2018; 31(4):e00088-17. https://doi.org/10.1128/CMR.00088-17 PMid:30068738 PMCid:PMC6148190

6. San Millan A, Evolution of plasmid-mediated antibiotic resistance in the clinical context, Trends in Microbiology, 2018; 26(12):978-985. https://doi.org/10.1016/j.tim.2018.06.007 PMid:30049587

7. Flemming HC, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S, Biofilms: an emergent form of bacterial life, Nature Reviews Microbiology, 2016; 14(9):563-575. https://doi.org/10.1038/nrmicro.2016.94 PMid:27510863

8. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al., CRISPR provides acquired resistance against viruses in prokaryotes, Science, 2007; 315(5819):1709-1712. https://doi.org/10.1126/science.1138140 PMid:17379808

9. Koonin EV, Makarova KS, Origins and evolution of CRISPR-Cas systems, Philosophical Transactions of the Royal Society B: Biological Sciences, 2019; 374(1772):20180087. https://doi.org/10.1098/rstb.2018.0087 PMid:30905284 PMCid:PMC6452270

10. Wahlgren M, Goel S, Akhouri RR, Variant surface antigens of Plasmodium falciparum and their roles in severe malaria, Nature Reviews Microbiology, 2017; 15(8):479-491. https://doi.org/10.1038/nrmicro.2017.47 PMid:28603279

11. de la Fuente-Núñez C, Silva ON, Lu TK, Franco OL, Antimicrobial peptides: role in human disease and potential as immunotherapies, Pharmacology & Therapeutics, 2017; 178:132-140. https://doi.org/10.1016/j.pharmthera.2017.04.002 PMid:28435091

12. Jiang F, Doudna JA, CRISPR-Cas9 structures and mechanisms, Annual Review of Biophysics, 2017; 46:505-529. https://doi.org/10.1146/annurev-biophys-062215-010822 PMid:28375731

13. Pickar-Oliver A, Gersbach CA, The next generation of CRISPR-Cas technologies and applications, Nature Reviews Molecular Cell Biology, 2019; 20(8):490-507. https://doi.org/10.1038/s41580-019-0131-5 PMid:31147612 PMCid:PMC7079207

14. Citorik RJ, Mimee M, Lu TK, Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases, Nature Biotechnology, 2014; 32(11):1141-1145. https://doi.org/10.1038/nbt.3011 PMid:25240928 PMCid:PMC4237163

15. Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, et al., Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials, Nature Biotechnology, 2014; 32(11):1146-1150. https://doi.org/10.1038/nbt.3043 PMid:25282355

16. Gomaa AA, Klumpe HE, Luo ML, Selle K, Barrangou R, Beisel CL, Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems, mBio, 2014; 5(1):e00928-13. https://doi.org/10.1128/mBio.00928-13 PMid:24473129 PMCid:PMC3903277

17. Yosef I, Manor M, Kiro R, Qimron U, Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria, Proceedings of the National Academy of Sciences, 2015; 112(23):7267-7272. https://doi.org/10.1073/pnas.1500107112 PMid:26060300 PMCid:PMC4466736

18. Kiga K, Tan XE, Ibarra-Chávez R, Watanabe S, Aiba Y, Sato’o Y, et al., Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria, Nature Communications, 2020; 11(1):2934. https://doi.org/10.1038/s41467-020-16731-6 PMid:32523110 PMCid:PMC7287087

19. Hao M, He Y, Zhang H, Liao XP, Liu YH, Sun J, et al., CRISPR-Cas9-mediated carbapenemase gene and plasmid curing in carbapenem-resistant Enterobacteriaceae, Antimicrobial Agents and Chemotherapy, 2020; 64(9):e00843-20. https://doi.org/10.1128/AAC.00843-20 PMid:32631827 PMCid:PMC7449206

20. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA, RNA-guided editing of bacterial genomes using CRISPR-Cas systems, Nature Biotechnology, 2013; 31(3):233-239. https://doi.org/10.1038/nbt.2508 PMid:23360965

21. Uribe RV, Rathmer C, Jahn LJ, Ellabaan MMH, Li SS, Sommer MOA, Bacterial resistance to CRISPR-Cas antimicrobials, Scientific Reports, 2021; 11(1):17267. https://doi.org/10.1038/s41598-021-96735-4 PMid:34446818 PMCid:PMC8390487

22. Frusteri Chiacchiera A, Casanova M, Bellato M, Piazza A, Migliavacca R, Batt G, et al., Harnessing CRISPR interference to resensitize laboratory strains and clinical isolates to last resort antibiotics, Scientific Reports, 2025; 15(1):261. https://doi.org/10.1038/s41598-024-81989-5 PMid:39747289 PMCid:PMC11696610

23. Ahmed MM, Kayode HH, Okesanya OJ, Ukoaka BM, Eshun G, Mourid MR, et al., CRISPR-Cas systems in the fight against antimicrobial resistance: current status, potentials, and future directions, Infection and Drug Resistance, 2024; 17:5229-5245. https://doi.org/10.2147/IDR.S494327 PMid:39619730 PMCid:PMC11608035

24. Wizrah MSI, CRISPR-Cas systems as next-generation antimicrobials: a systemic review of mechanisms, delivery strategies, and translational challenges, Frontiers in Microbiology, 2026; 17:1747931. https://doi.org/10.3389/fmicb.2026.1747931 PMid:42199538 PMCid:PMC13199036

25. Almufarriji FM, Nanocarrier-mediated CRISPR-Cas delivery: a novel approach against antibiotic-resistant superbugs, Saudi Pharmaceutical Journal, 2026; 34(1):101895. https://doi.org/10.1007/s44446-026-00064-4 PMid:41604096 PMCid:PMC12852552

26. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R, Engineering precision nanoparticles for drug delivery, Nature Reviews Drug Discovery, 2021; 20(2):101-124. https://doi.org/10.1038/s41573-020-0090-8 PMid:33277608

27. Mout R, Ray M, Yesilbag Tonga G, Lee YW, Tay T, Sasaki K, et al., Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing, ACS Nano, 2017; 11(3):2452-2458. https://doi.org/10.1021/acsnano.6b07600 PMid:28129503

28. Lee K, Conboy M, Park HM, Jiang F, Kim HJ, Dewitt MA, et al., Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair, Nature Biomedical Engineering, 2017; 1(11):889-901. https://doi.org/10.1038/s41551-017-0137-2 PMid:29805845

29. Kulkarni JA, Cullis PR, van der Meel R, Lipid nanoparticles enabling gene therapies: from concepts to clinical utility, Nucleic Acid Therapeutics, 2018; 28(3):146-157. https://doi.org/10.1089/nat.2018.0721 PMid:29683383

30. Pardi N, Hogan MJ, Porter FW, Weissman D, mRNA vaccines-a new era in vaccinology, Nature Reviews Drug Discovery, 2018; 17(4):261-279. https://doi.org/10.1038/nrd.2017.243 PMid:29326426

31. Mura S, Nicolas J, Couvreur P, Stimuli-responsive nanocarriers for drug delivery, Nature Materials, 2013; 12(11):991-1003. https://doi.org/10.1038/nmat3776 PMid:24150417

32. Riley RS, June CH, Langer R, Mitchell MJ, Delivery technologies for cancer immunotherapy, Nature Reviews Drug Discovery, 2019; 18(3):175-196. https://doi.org/10.1038/s41573-018-0006-z PMid:30622344 PMCid:PMC6410566

33. Allen TM, Cullis PR, Liposomal drug delivery systems: from concept to clinical applications, Advanced Drug Delivery Reviews, 2013; 65(1):36-48. https://doi.org/10.1016/j.addr.2012.09.037 PMid:23036225 PMCid:PMC10539472

34. Ahmad J, Singhal M, Amin S, Rizwanullah M, Akhter S, Kamal MA, et al., Bile salt stabilized vesicles (bilosomes): a novel nano-pharmaceutical design for oral delivery of proteins and peptides, Current Pharmaceutical Design, 2017; 23(11):1575-1588. https://doi.org/10.2174/1381612823666170124111142 PMid:28120725

35. Kaurav H, Tripathi M, Kaur SD, Bansal A, Kapoor DN, Sheth S, Emerging trends in bilosomes as therapeutic drug delivery systems, Pharmaceutics, 2024; 16(6):697. https://doi.org/10.3390/pharmaceutics16060697 PMid:38931820 PMCid:PMC11206586

36. Obeid MA, Teeravatcharoenchai T, Connell D, et al., Examination of the effect of niosome preparation methods in encapsulating model antigens on the vesicle characteristics and their ability to induce immune responses, Journal of Liposome Research, 2021; 31(2):195-202. https://doi.org/10.1080/08982104.2020.1768110 PMid:32396752

37. Zarenezhad E, Marzi M, Abdulabbas HT, Jasim SA, Kouhpayeh SA, Barbaresi S, et al., Bilosomes as nanocarriers for the drug and vaccine delivery against gastrointestinal infections: opportunities and challenges, Journal of Functional Biomaterials, 2023; 14(9):453. https://doi.org/10.3390/jfb14090453 PMid:37754867 PMCid:PMC10531812

38. Nayak D, Rathnanand M, Tippavajhala VK, Unlocking the potential of bilosomes and modified bilosomes: a comprehensive journey into advanced drug delivery trends, AAPS PharmSciTech, 2023; 24(8):238. https://doi.org/10.1208/s12249-023-02696-4 PMid:37989979

39. Zafar A, Alsaidan OA, Mohamed MS, Yasir M, Khalid M, Development of gentamicin bilosomes laden in situ gel for topical ocular delivery: optimization, in vitro characterization, toxicity, and anti-microbial evaluation, Advanced Pharmaceutical Bulletin, 2024; 14(3):646-664. https://doi.org/10.34172/apb.2024.057 PMid:39494264 PMCid:PMC11530890

40. Zohdy MH, El-Kamel AH, Alseqely M, Bakr BA, Heikal LA, Bilosomal delivery of thymol-glycyrrhetinic acid: a multifaceted strategy to combat multidrug-resistant wound infections, Journal of Pharmaceutical Investigation, 2026; 56(3):367-391. https://doi.org/10.1007/s40005-025-00741-x

41. Marino ND, Zhang JY, Borges AL, Sousa AA, Leon LM, Rauch BJ, et al., Discovery of widespread type I and type V CRISPR-Cas inhibitors, Science, 2018; 362(6411):240-242. https://doi.org/10.1126/science.aau5174 PMid:30190308 PMCid:PMC6520112

42. Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al., Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo, Nature Biotechnology, 2015; 33(1):73-80. https://doi.org/10.1038/nbt.3081 PMid:25357182 PMCid:PMC4289409

43. Wang HX, Li M, Lee CM, Chakraborty S, Kim HW, Bao G, et al., CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery, Chemical Reviews, 2017; 117(15):9874-9906. https://doi.org/10.1021/acs.chemrev.6b00799 PMid:28640612 PMCid:PMC11043507

44. Wang P, Zhang L, Xie Y, Wang N, Tang R, Zheng W, et al., Genome editing for cancer therapy: delivery of Cas9 protein/sgRNA plasmid via a gold nanocluster/lipid core-shell nanocarrier, Advanced Science, 2017; 4(11):1700175. https://doi.org/10.1002/advs.201700175 PMid:29201613 PMCid:PMC5700650

45. Sun L, He T, Zhang L, Pang M, Zhang Q, Zhou Y, et al., Generation of newly discovered resistance gene mcr-1 knockout in Escherichia coli using the CRISPR/Cas9 system, Journal of Microbiology and Biotechnology, 2017; 27(7):1276-1280. https://doi.org/10.4014/jmb.1611.11021 PMid:28535607

46. Dong H, Chai D, Guan X, Guo J, Gao H, Lin H, et al., Elimination of colistin resistance gene mcr-1 in Escherichia coli by CRISPR-Cas9, Frontiers in Microbiology, 2019; 10:2314

Published

2026-11-15
Statistics
Abstract Display: 0
PDF Downloads: 0
PDF Downloads: 0

How to Cite

1.
Pan D, Sarkar S, De B, Mia A, Das R, Guha S, et al. CRISPR-Enabled Nanocarrier Systems Against Multidrug-Resistant Bacteria: Emerging Potential of Bilosomes for Precision Antimicrobial Therapy. J. Drug Delivery Ther. [Internet]. 2026 Nov. 15 [cited 2026 Nov. 16];16(11):143-5. Available from: https://www.jddtonline.info/index.php/jddt/article/view/8085

How to Cite

1.
Pan D, Sarkar S, De B, Mia A, Das R, Guha S, et al. CRISPR-Enabled Nanocarrier Systems Against Multidrug-Resistant Bacteria: Emerging Potential of Bilosomes for Precision Antimicrobial Therapy. J. Drug Delivery Ther. [Internet]. 2026 Nov. 15 [cited 2026 Nov. 16];16(11):143-5. Available from: https://www.jddtonline.info/index.php/jddt/article/view/8085